- Home
- PFO vs ADAG Comparison
PFO vs ADAG Comparison
Compare PFO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFO | ADAG |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PFO | ADAG |
|---|---|---|
| Price | $9.41 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 31.8K | ★ 61.0K |
| Earning Date | 01-01-0001 | 08-12-2025 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.90 | $1.30 |
| 52 Week High | $8.51 | $3.16 |
Technical Indicators
Market Signals| Indicator | PFO | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 48.48 |
| Support Level | $9.33 | $1.76 |
| Resistance Level | $9.47 | $1.93 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 37.21 | 48.94 |
Price Performance
Historical ComparisonAbout PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.